Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQFI.L Regulatory News (QFI)

  • There is currently no data for QFI

AGM Statement

25 Nov 2022 07:00

RNS Number : 5674H
Quadrise Fuels International PLC
25 November 2022
 

25 November 2022

Quadrise Fuels International plc

("Quadrise", "QFI", the "Company" and together with its subsidiaries the "Group")

 

AGM Statement

 

Quadrise Fuels International plc (AIM:QFI), the supplier of innovative energy solutions for a cleaner planet, is pleased to provide the following update ahead of the Company's Annual General Meeting ("AGM") which commences today at 12 noon.

 

At the conclusion of the AGM, the Company will provide a business update presentation to shareholders present at the venue and online via the Investor Meet Company ("IMC") platform. The presentation is open to all existing and potential investors. Those wishing to attend online via IMC can register via: www.investormeetcompany.com/quadrise-fuels-international-plc/register-investor.

 

2022 Overview and Update

 

Business Development

Throughout the financial year ended 30 June 2022 ("FY22") and since the period end, Quadrise has seen material progress across its portfolio of international projects. With the advancement of these projects, Quadrise expects to achieve commercial revenues in its current financial year.

 

Key projects:

· Morocco - In June 2022, Quadrise signed a new Material Transfer & Cooperation Agreement with the client. The initial industrial demonstration test is now scheduled to be completed next month. Upon success, the parties will enter discussions for potential commercial supply, with a view to signing a fuel supply agreement in the first quarter of calendar year 2023.

· MSC - In July 2022, Quadrise signed a Framework Agreement with MSC Shipmanagement ("MSC") to carry out trials of bioMSAR™ and MSAR® with a view to the commercial supply of one or both fuels to MSC's global fleet. Proof-of-concept tests are planned for H1 2023, following which MSC will run Letter of No Objection trials starting with bioMSAR™. Discussions are now underway with third parties regarding the production of the fuel for the trials. With positive trial progression, Quadrise, MSC, and other key stakeholders expect to commence discussions for commercial supply to MSC's fleet in H2 2023.

· Utah - In April 2022, Quadrise entered into a Commercial Development Agreement with Valkor Technologies LLC to commercialise both MSAR® and bioMSAR™ at its projects in Utah. The Company is targeting a commercial agreement by the end of January for the licensed supply of a Manufacturing Unit to provide fuel for MSAR® and bioMSAR™ trials as a precursor to commercial supply during 2023.

· Americas - Quadrise and its local agents are advancing discussions with candidate sites in Panama and Honduras to trial MSAR® and bioMSAR™ at power plants in H1 2023 as a precursor to potential commercial supply agreements later in the year. Joint discussions are also underway with a large refinery in the Caribbean with an interest in potential MSAR® supply and the Company continues its efforts to progress activities in Mexico.

· bioMSAR™, bioMSAR Zero & RDI -Testing of glycerine-based bioMSAR™ in relation to the MSC project has been successfully completed by Wärtsilä and affiliates at test facilities in Italy. Final test reports are expected before the end of 2022. Aquafuel diesel engine testing on bioMSAR and other fuel and biofuel formulations to support the new Quadrise Blend-on-Board solution is also scheduled to be completed before the end of the year.

In September 2022, Quadrise signed a Joint Development Agreement with Vertoro to investigate the use of their crude sugar oils as an alternative biofuel feedstock for bioMSAR™. RDI work continues on our bioMSAR™ Zero solution for 2030 at our QRF laboratories.

 

Commenting on the update, Jason Miles, Chief Executive Officer of QFI, said:

 

"During the period we have made substantial progress with each of our key projects, whilst also positioning ourselves to be one of the key decarbonisation solution providers in a rapidly changing global energy market, as set out in our recent inaugural Sustainability Report.

The pace of decarbonisation and the escalating price of energy is creating a significant opportunity to commercialise our innovative fuel and biofuel solutions, as they offer clients the ability to reduce energy costs and greenhouse gas emissions immediately to help them accelerate the transition to net-zero.

The Company is entering a notably exciting period, with the progression of our core projects expected to deliver commercial revenues in the current financial year. Beyond these projects, we continue to invest and collaborate in research and development to enhance our intellectual property portfolio and advance our decarbonisation technologies to ultimately deliver net-zero carbon solutions by 2030.

On behalf of the board, I would like to thank our loyal shareholders for their continued support, and I look forward to seeing many of you at the AGM in person."

 

For additional information, please contact:

 

Quadrise Fuels International Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Executive Officer

Nominated Adviser

Cenkos Securities plc

+44 (0)20 7397 8900

Ben Jeynes

Katy Birkin

Broker

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs

Fiona Conroy

Public & Investor Relations

 

Vigo Consulting

Patrick D'Ancona

Charlie Neish

+44 (0)20 7390 0230

 

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to reduce energy costs and greenhouse gas emissions today for clients in the global power generation, shipping, industrial and refining industries.

 

Learn more: www.quadrisefuels.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMFEFEFLEESEDF
Date   Source Headline
2nd Feb 20217:00 amRNSUpdate re Morocco and Greenfield Energy Projects
1st Feb 20217:00 amRNSUpdate re bioMSAR Testing at Aquafuel Research Ltd
27th Jan 20217:00 amRNSIssue of Equity
21st Jan 20217:00 amRNSJoint Development Agreement - MSC Shipmanagement
6th Jan 20217:00 amRNSIssue of Equity
4th Jan 20217:00 amRNSChange of Registered Office
18th Dec 202011:46 amRNSUpdate re Greenfield MSAR Trial
18th Dec 20207:00 amRNSbioMSAR Testing Update & Collaboration Agreement
15th Dec 20207:00 amRNSLaunch of bioMSAR
3rd Dec 20207:00 amRNSPublication of Americas White Paper
27th Nov 202012:13 pmRNSResult of AGM
27th Nov 20207:00 amRNSAGM Statement
24th Nov 20208:00 amEQSQuadrise Fuels International (QFI): The clean solution to a global problem
2nd Nov 20205:23 pmRNSPosting of Annual Report and Notice of AGM
26th Oct 20207:00 amRNSMorocco Update
5th Oct 20207:00 amRNSFinal Results, Investor Presentation & AGM Notice
7th Sep 20205:56 pmRNSIssue of Equity
7th Sep 20207:00 amRNSNotice of Results, Update and Investor Event
24th Aug 20207:00 amRNSIssue of Share Options
20th Aug 20207:00 amRNSIssue of Equity
18th Aug 20207:22 amRNSGreenfield MSAR Commercial Trial Agreement
17th Aug 20207:00 amRNSPublication of White Paper
17th Jul 20203:59 pmRNSInvestor Presentation
30th Jun 20209:18 amRNSHolding(s) in Company
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:37 pmRNSPrice Monitoring Extension
23rd Jun 20207:00 amRNSIssue of Equity
18th Jun 20207:00 amRNSStatement re MSAR Licensing and Upstream Trial
17th Jun 20201:47 pmRNSStatement re MSAR Licensing
2nd Jun 20207:00 amRNSInvestor Presentation
1st May 20207:00 amRNSFurther Statement re Covid-19 and Update
16th Apr 20202:21 pmRNSIssue of Equity
15th Apr 20207:00 amRNSDirectorate Change
30th Mar 20204:13 pmRNSNew Website
30th Mar 202011:02 amRNSHalf-year Report - Replacement
30th Mar 20207:00 amRNSHalf-year Report
24th Mar 202010:13 amRNSIssue of Equity
16th Mar 20207:00 amRNSStatement re Covid-19 and Morocco Pilot Trial
5th Mar 20209:10 amRNSUpdate on Morocco Pilot Trial
17th Feb 20207:00 amRNSNotice of Interim Results and Business Update
30th Jan 20207:00 amRNSAppointment of New Auditors
15th Jan 20207:00 amRNSDirectorate Changes
16th Dec 20198:38 amRNSDirectorate Change
29th Nov 20194:42 pmRNSResult of AGM
29th Nov 20197:05 amRNSIssue of Warrants
29th Nov 20197:00 amRNSMaterial Transfer & Cooperation Agreement
29th Nov 20197:00 amRNSAGM Update
6th Nov 20195:03 pmRNSPosting of Annual Report and Notice of AGM
10th Oct 20195:42 pmRNSHolding(s) in Company
8th Oct 20197:00 amRNSNew three-year Exclusive Agreement with Nouryon

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.